Rubriche
Primo Piano
TecnoLogicaMente Comunicati stampa Wireless Internet e-Government Scuola hi-tech Economia Prodotti Eventi Videogiochi Approfondimenti Speciali Interviste Diritto del web Recensioni Telefonia Curiosità Ultime di agenzia Finanza e mercati European News ![]() Asian News ![]() JCN Newswire ![]() Hugin ![]() Servizi stampa
Per i giornalisti
Per i portali Accredito azienda Elenco accrediti/VPO Servizio IDC Abbonamento IDC Invio comunicati Risorse e servizi
|
Unique New Gel Combination Provides Relief For Distressing Scalp ConditionNotizia pubblicata in rete il 10/11/2008 00:01, tempo medio di lettura previsto 4 minuti e 41 secondiLONDON, November 10 /PRNewswire/ -- LONDON, November 10 /PRNewswire/ -- A new, once-daily treatment gel is available on prescription today for the itching, flaking and soreness caused by the common condition scalp psoriasis. Xamiol(R) gel (pronounced "zamiol"), containing calcipotriol and betamethasone dipropionate, combines the effects of a Vitamin D-like ingredient to help normalise the speed at which skin cells are produced and a steroid to reduce inflammation. Typical scalp psoriasis treatments include coal tar, dithranol, salicylic acid, steroid creams and ointments, as well as Vitamin D based treatments.(1) In the past, patients have expressed their dissatisfaction with certain treatments, for being ineffective, difficult to apply, making the hair look dirty or smelling strongly. This in turn can affect their willingness to stick to treatment routines.(2) This new combination is an almost clear and odourless gel that is simply applied once-daily: for example in the evening, then left on overnight and washed out the following morning. "The Psoriasis Association welcomes the introduction of new therapies such as Xamiol(R) that can improve the quality of life of patients and expand the treatment options for this frustrating and traditionally difficult to treat condition", commented Helen McAteer, Information Officer for the Psoriasis Association. Dr Girish Gupta, Consultant Dermatologist from Monklands Hospital, Lanarkshire added, "the gel formulation makes it easy for people to use; very often they may stop treatment if it is messy or makes the hair look greasy or smell unpleasant. An effective new treatment will be welcomed by sufferers of this uncomfortable and often embarrassing scalp condition." Psoriasis affects 1.2 million people in the UK and up to 80% of these will have scalp psoriasis.(3) Thick skin scales, itching and redness may develop across the scalp, around the hairline, forehead, neck and behind the ears.(1) Being such a visible condition, scalp psoriasis impacts on quality of life - sufferers feel self-conscious, may avoid social situations and can feel isolated and depressed.(2) "Apart from the itchiness and discomfort, the worst thing about scalp psoriasis is how visible it is - people stare at you, and they mistakenly think that the psoriasis is contagious" said Sally McCulloch, aged 51 from London. "I feel so self-conscious with redness across the top of my forehead and thick, white, scaly skin across my scalp. It's reassuring to have new treatments, especially if they're easy to use, and won't leave me with greasy, lank hair." The unique gel combination is manufactured by LEO Pharma and is available on prescription for the topical treatment of scalp psoriasis in adults. It is applied to affected areas of the scalp once-daily for four weeks. After this period, repeated treatment can be initiated under medical supervision.(4) Notes to Editors About psoriasis and scalp psoriasis - Psoriasis affects approximately 1.2 million people in the UK including celebrities such as Sunday Night Project presenters Justin Lee Collins and Alan Carr. - Up to 80% of psoriasis sufferers will have the condition on their scalp.3 - Scalp psoriasis can be distressing for patients to live with because of its visibility; despite a range of therapy options, scalp psoriasis remains difficult to treat.(5) About LEO Pharma LEO Pharma this year celebrates its centenary. Xamiol(R) gel adds to its existing portfolio of dermatology treatments, which include Dovobet(R) (calcipotriol /betamethasone dipropionate), a combination treatment for psoriasis, Dovonex(R) (calcipotriol) for psoriasis, and Fucidin(R) (fusidic acid), an antibiotic used alone for impetigo or in combination with hydrocortisone (Fucidin(R) H) or betamethasone valerate (Fucibet(R)) for infected eczema. Further sources of information - The Psoriasis Association is the leading national membership organisation for people affected by psoriasis - patients, families, carers and health professionals. This year, Psoriasis Awareness Week marks the 40th anniversary of the Psoriasis Association. http://www.psoriasis-association.org.uk. - The Skin Care Campaign (SCC) is an umbrella organisation representing the interests of all people with skin diseases in the UK. http://www.skincarecampaign.org - PSALV - Psoriasis Scotland Arthritis Link Volunteers. http://webplus.psoriasisscotland.org.uk References (1) Psoriasis Association. Scalp Psoriasis patient leaflet. January 2008. (2) Data on file: market research conducted by Hall & Partners Healthcare for LEO Pharma. March 2008. (3) van de Kerkhof PCM, Steegers-Theunissen RPM, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197: 31-36. (4) LEO Pharma. Xamiol(R) Summary of Product Characteristics. September 2008. (5) Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol 2007; 21: 1151-1160. For Further enquires please call LEO Pharma +44-18-44347-333 For further information please contact: Jennie Conway, Athena Medical PR, Tel: +44(0)20-8956-2861, jennie@athenamedicalpr.com; Steven Dwyer, Athena Medical PR, Tel: +44(0)20-8956-2227, steven@athenamedicalpr.com
Copyright: 2010 PR Newswire Europe. All rights to PR Newswire Content are owned by PR Newswire Association LLC and/or its Affiliates or used under l
icence from their licensors. Any copying or other use of PR Newswire Content including without limitation by caching, framing, linking or otherwise is expressly forbidden
without the prior written consent of PR Newswire Europe Limited or an appropriate Affiliate.
Ultime notizie
14/03/2010 14:56 F1: Domenicali esulta, grande Ferrari ma e' solo prima gara14/03/2010 14:49 Ue: a Ecofin aiuti alla Grecia e ricerca accordo su hedge fund 14/03/2010 14:48 Firenze: studente americano ubriaco cade da finestra, e' gravissimo 14/03/2010 14:47 F1: Gp Bahrain, Alonso trionfa e doppietta Ferrari 14/03/2010 14:42 Pakistan: raid aereo contro rifugi talebani, 16 morti 14/03/2010 14:19 Sanita': lievissimo malore per cardinal Martini a cerimonia don Verze' 14/03/2010 14:11 Viminale: Maroni domani a Malpensa per primo body scanner 14/03/2010 14:09 Berlusconi: don Verze', statista solo per amor di patria 14/03/2010 13:25 Berlusconi: premier, don Verze' mi assolve dai peccati senza che io dica niente 14/03/2010 13:03 Regionali: Berlusconi, c'e' una atmosfera avvelenata 14/03/2010 13:01 Regionali: Berlusconi, c'e' una atmosfera avvelenata 14/03/2010 12:32 Francia: al voto per regionali, Sarkozy rischia una pesante sconfitta 14/03/2010 12:18 Papa: ateismo puo' nascondere esigenza di scoprire volto di Dio 14/03/2010 12:17 Atletica: Marcia, Schwazer migliora record italiano 20 km 14/03/2010 12:15 Hutchison Whampoa Group and Hutchison Telecom International Announced Despatch of Proposed Privatisation Scheme Document |
|
|||||||||||||||||||||||||
| |||||||||||||||||||||||||||


